Interprofessional Care of Patients with Hereditary Transthyretin Amyloidosis

To participate in this activity, please:

Log in Sign Up

A progressive disease, hereditary transthyretin amyloidosis (ATTRv), impacts multiple organ systems and places a large emotional, financial, and physical burden on patients, thereby necessitating that care is provided by an interprofessional, multidisciplinary care team. This activity highlights key concepts in managing patients with ATTRv, provides an overview of the principles of interprofessional collaboration, and highlights reports describing the composition and role of interprofessional, multidisciplinary care team members to address the diverse needs of persons with ATTRv.

Please visit our related course, Improving the Recognition, Diagnosis, and Treatment of Hereditary Transthyretin Amyloidosis, by clicking here.

Course Credit:

0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours

Dates:

Opens: 2026-05-01
Closes: 2027-05-01

Target Audience:

Nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients with transthyretin amyloidosis

This activity was self-funded by Annenberg Center for Health Sciences.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 hours AAPA Category 1 CME credits. Approval is valid until May 01, 2027. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.25 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Rinita H. Acevedo, PharmD (Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Christopher Flores, MD

    Family Medicine Physician
    Eisenhower Medical Center
    Rancho Mirage, California

  • Michelle Kaku, MD headshot

    Michelle Kaku, MD

    Associate Professor of Neurology
    Vice Chair for Education, Neurology Department
    Icahn School of Medicine at Mount Sinai
    New York, New York

  • LaTosha Mollette, DNP

    Family Nurse Practitioner
    Louisiana Family Medicine Clinic
    Jonesboro, Louisiana

  • Michael Smith, PharmD

    Clinical Pharmacist in Pain/Palliative Care
    University of Michigan
    Ann Arbor, Michigan

Learning Objectives

  • Describe the evolution in the treatment landscape for patients with transthyretin amyloidosis
  • Identify strategies to improve interprofessional care of patients with transthyretin amyloidosis

Faculty Disclosures

Christopher Flores, MD

No relationships to disclose.

Michelle Kaku, MD

Advisory Board: AstraZeneca, Intellia


LaTosha Mollette, DNP

No relationships to disclose.

Michael Smith, PharmD

No relationships to disclose.